Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study

2016 ◽  
Vol 16 (6) ◽  
pp. 514-519 ◽  
Author(s):  
Christian F. Jehn ◽  
Philipp Hemmati ◽  
Silvia Lehenbauer-Dehm ◽  
Sherko Kümmel ◽  
Bernd Flath ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liposomal Doxorubicin ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Heavily Pretreated

scholarly journals Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study

2012 ◽  
Vol 23 (10) ◽  
pp. 2599-2605 ◽  
Author(s):  
R.P. Collea ◽  
F.W. Kruter ◽  
J.E. Cantrell ◽  
T.K. George ◽  
S. Kruger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin

scholarly journals A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer

Cancer ◽  
2010 ◽  
Vol 116 (6) ◽  
pp. 1440-1445 ◽  
Author(s):  
Gabriel N. Hortobagyi ◽  
William Heim ◽  
Laura Hutchins ◽  
Edgardo Rivera ◽  
Bernard Mason ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Fixed Combination ◽  
Metastatic Breast ◽  
Daily Regimen ◽  
Phase 2 ◽  
Phase 2 Study

scholarly journals Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3509
Author(s):  
Elena López-Miranda ◽  
José Manuel Pérez-García ◽  
Serena Di Cosimo ◽  
Etienne Brain ◽  
Maja Ravnik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liposomal Doxorubicin ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin ◽  
Maximum Tolerated Dose ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Open Label ◽  
Phase Ib

The paper assesses the dose-limiting toxicities and the maximum tolerated dose (MTD) of trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal doxorubicin (NPLD) in HER2-positive (HER2+) metastatic breast cancer (MBC). This single-arm, open-label, phase Ib trial (NCT02562378) enrolled anthracycline-naïve HER2+ MBC patients who had progressed on trastuzumab and taxanes. Patients received a maximum of 6 cycles of NPLD intravenously (IV) at various dose levels (45, 50, and 60 mg/m2) in the “3 plus 3” dose-escalation part. During expansion, they received 60 mg/m2 of NPLD every 3 weeks (Q3W) plus standard doses of T-DM1. The MTD was T-DM1 3.6 mg/kg plus NPLD 60 mg/m2 administered IV Q3W. No clinically relevant worsening of cardiac function was observed. Among all evaluable patients, the overall response rate was 40.0% (95%CI, 16.3–67.7) with a median duration of response of 6.9 months (95%CI, 4.8–9.1). Clinical benefit rate was 66.7% (95%CI, 38.4–88.2) and median progression-free survival was 7.2 months (95%CI, 4.5–9.6). No significant influence of NPLD on T-DM1 pharmacokinetics was observed. The addition of NPLD to T-DM1 is feasible but does not seem to improve the antitumor efficacy of T-DM1 in HER2+ MBC patients.

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

2020 ◽  
Vol 20 (3) ◽  
pp. 228-237 ◽  
Author(s):  
Noha Rashad ◽  
Thoraya Abdelhamid ◽  
Samia A. Shouman ◽  
Hanan Nassar ◽  
Mervat A. Omran ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Study ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document